DivestmentApr 22, 2026, 07:06 AM
Certara Divests Medical Writing Business for $100M Cash + $35M Earn-out
AI Summary
Certara, Inc. has entered into a Purchase Agreement with Veristat, LLC to divest its global medical writing and related regulatory services business. The transaction involves Certara selling the equity interests of certain subsidiaries and related assets for an aggregate cash consideration of $100 million, subject to post-closing adjustments. Additionally, Certara could receive up to $35 million in contingent earn-out consideration based on the business's future financial performance. The closing is subject to customary conditions, including internal reorganization steps.
Key Highlights
- Certara to sell its global medical writing and related regulatory services business.
- Veristat, LLC will pay $100 million in cash consideration at closing.
- Additional contingent consideration of up to $35 million earn-out based on performance.
- Up to $15 million of the purchase price may be held in escrow.
- Transaction involves the sale of equity interests in certain subsidiaries and assets.
Price Impact
More from CERT